As FDA panel looks on favorably, Pfizer hopes it will be second time lucky for Mylotarg

12 July 2017
2019_biotech_test_vial_discovery_big

The Oncologic Drug Advisory Committee (ODAC) of the US Food and Drug Administration has provided a positive opinion on Mylotarg (gemtuzumab ozogamicin).

The advisory panel determined that, based on data from the pivotal ALFA-0701 study, the drug candidate has a favorable risk/benefit profile as an adjunctive therapy for certain newly-diagnosed acute myeloid leukemia (AML) patients.

The drug is an antibody-drug conjugate under development by New York-based Pfizer (NYSE: PFE), comprised of a cytotoxic agent attached to a monoclonal antibody.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology